Conversion therapy of Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6 in patients with liver metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2620139
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Chemotherapy with Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6. Treatment repeats every 14 days for up to 12 courses (6 courses for Cetuximab plus FOLFIRI and 6 courses for Bevacizumab plus mFOLFOX6) . Liver resection (if possible)
Primary outcome(s): Liver resection rate after chemotherapy with Bevacizumab plus mFOLFOX6(R0/R1)
Study Design: Single arm Non-randomized
创建时间：
2010-12-15
